The study by Mabey et al., “Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors,” presented a longitudinal clinical ...

In an interactive session at Becker's 12th Annual CEO + CFO Roundtable, two leaders from — Mike Kreitzinger, lead of health system strategy, and Damon Hostin, lead of market access for health systems ...

Myriad Genetics’ RiskScore named one of the top 10 significant advances in genomic medicine: Salt Lake City Monday, December 23, 2024, 11:00 Hrs [IST] Myriad Genetics, Inc, a le ...

You may be familiar with a range of tips for living a healthy life: Watch your weight, exercise, eat nutritious food and don’t smoke, for example.

Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium.

According to the latest study from BCC Research, "Global Multiomics Market" is expected to grow from $2.7 billion in 2024 to $5.1 billion by the end of 2029, at a compound annual growth rate of 13.5%.

These cover from genetic testing and precision medicine to the growing integration ... trends of 2024 has been the increasing emphasis on personalized medicine, and adoption of genomics especially for ...

Tempus AI offers innovative healthcare technology with strong long-term potential despite recent stock volatility. Read why ...

Dr. Doug Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Cancer Center, overseeing clinical ...

In a triumph for precision medicine, a pioneering study has unlocked the potential to revolutionize breast cancer treatment. By advancing the ...